Brief: Active Biotech Receives Orphan Drug Designation

Active Biotech AB publ

18/05/2022 14:43

May 18 (Reuters) - Active Biotech AB publ  ACTI.ST :
    * FDA GRANTS ORPHAN DRUG DESIGNATION FOR TASQUINIMOD IN
MYELOFIBROSIS
    * THIS DESIGNATION PROVIDES FOR A SEVEN-YEAR MARKETING
EXCLUSIVITY
PERIOD AGAINST COMPETITION, AS WELL AS CERTAIN INCENTIVES
    * WITH ERASMUS MC HAVE INITIATED A RESEARCH COLLABORATION
WITH
TASQUINIMOD IN MYELOFIBROSIS, THAT INCLUDES PRECLINICAL STUDIES
AS WELL AS A CLINICAL PROOF OF CONCEPT STUDY IN PATIENTS WITH
MYELOFIBROSIS
    * CLINICAL STUDY WILL BE FINANCED BY ONCODE AND IS PLANNED
TO
START EARLY 2023

Source text for Eikon:  ID:nGNE7rqSkV 
Further company coverage:  ACTI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))